Vaccine: there are questions, but let’s not spoil the mood: a powerful macro and market performance driver

English -

17 Nov 2020

As we said in our editorial released in the wake of the news of Pfizer-BioNTech’s new vaccine six days ago , the announcement is obviously excellent news and we are not going back on that. Nevertheless, we need to look at the uncertainties liable to shape decision-makers’ and investors’ expectations over the next few months.

Investment strategy

Contact us

Our strategist economists are at your disposal

+33 1 53 42 65 33


France's leading independent research company in macroeconomics and investment strategy.